Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXACT SCIENCES CORPORATION

(EXAS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
125.01(c) 122.57(c) 120.38(c) 126.9(c) 126.52(c) Last
1 161 678 1 078 652 1 569 529 1 518 299 1 453 648 Volume
+2.56% -1.95% -1.79% +5.42% -0.30% Change
More quotes
Financials (USD)
Sales 2021 1 721 M - -
Net income 2021 -461 M - -
Net Debt 2021 1 201 M - -
P/E ratio 2021 -43,3x
Yield 2021 -
Sales 2022 2 132 M - -
Net income 2022 -439 M - -
Net Debt 2022 1 474 M - -
P/E ratio 2022 -50,1x
Yield 2022 -
Capitalization 21 705 M 21 705 M -
EV / Sales 2021 13,3x
EV / Sales 2022 10,9x
Nbr of Employees 4 900
Free-Float 99,0%
More Financials
Company
Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to... 
More about the company
Ratings of Exact Sciences Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about EXACT SCIENCES CORPORATION
06/15EXACT SCIENCESá : Raymond James Initiates Coverage on Exact Sciences With Strong..
MT
06/14INSIDER TRENDS : Insider at Exact Sciences Converts Options Amid 90-Day Selling ..
MT
06/04EXACT SCIENCESá : Insider Sales at Exact Sciences (EXAS) are Significant and Ext..
MT
06/03INSIDER TRENDS : Selling By Insiders Lingers at Exact Sciences
MT
06/03INSIDER TRENDS : 90-Day Insider Selling Trend Prolonged at Exact Sciences
MT
06/03EXACT SCIENCESá : Goldman Sachs Starts Exact Sciences at Buy With $160 Price Tar..
MT
05/26EXACT SCIENCESá : New Analysis Reinforces Cost-Effectiveness of the Oncotype DX ..
PU
05/26EXACT SCIENCESá : Strengthens Evidence Supporting Cologuard« and Oncotype DX« Te..
PU
05/25EXACT SCIENCESá : Wells Fargo Initiates Exact Sciences at Equal-Weight With $115..
MT
05/24EXACT SCIENCESá : to participate in June investor conferences
PR
05/21EXACT SCIENCESá : Presents Modeling Data Showing Cologuard 'Superior' for Colore..
MT
05/20EXACT SCIENCESá : New Analysis Reinforces Cost-Effectiveness of the Oncotype DX ..
PU
05/19EXACT SCIENCESá : Applauds Final Task Force Recommendation That Lowers Starting ..
PU
05/18EXACT SCIENCESá : New Analysis Reinforces Cost-Effectiveness of the Oncotype DX ..
PU
05/12EXACT SCIENCESá : Truist Securities Adjusts Exact Sciences' Price Target to $168..
MT
More news
News in other languages on EXACT SCIENCES CORPORATION
2019STOCK MARKET PARIS : Attention, semaine très chargée !
2019EN DIRECT DES MARCHESá: Sanofi, Airbus, Air France KLM, CNP, Refinitiv, Mylan..
2014Wall Street en légère baisse, l'Ukraine toujours en ligne de mire
2014Les valeurs à suivre sur les marchés américains
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 153,68 $
Last Close Price 126,52 $
Spread / Highest target 46,2%
Spread / Average Target 21,5%
Spread / Lowest Target -39,9%
EPS Revisions
Managers and Directors
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION-4.51%21 705
GUARDANT HEALTH, INC.-6.73%12 155
BGI GENOMICS CO., LTD.-7.47%7 557
INVITAE CORPORATION-21.57%6 553
ADAPTIVE BIOTECHNOLOGIES CORPORATION-33.28%5 535
CAREDX, INC22.35%4 614